Inflammasome Therapeutics is focused on developing therapies for degenerative diseases such as Alzheimer’s disease, multiple sclerosis, macular degeneration, and Parkinson's disease.

Inflammasome Therapeutics

Vision Biotechnology specializes in developing and manufacturing diagnostic test kits for healthcare professionals to accurately diagnose various diseases. The company incorporates the latest advancements in biotechnology into its products, self-described as elevating healthcare through innovative testing solutions.

Vision Biotechnology

Inflammasome Therapeutics | 341 followers on LinkedIn. Cutting edge treatment for eye diseases and more | Inflammasome Therapeutics is a science based company founded to develop therapies for prevalent, degenerative diseases such as Alzheimer’s disease, multiple sclerosis, macular degeneration, and Parkinson&#39;s disease.

President and CEO at Inflammasome Therapeutics, Ltd.

Paul Ashton

Inflammasome Therapeutics marks the second clinical trial underway with their new drug. Great things are happening at Inflammasome.

Inflammasome Therapeutics announces first patient dosed in Phase 1 Diabetic Macula Edema Study of the Dual Inflammasome Inhibitor K8

Inflammasome Therapeutics has received FDA approval to launch a phase 1/2 first-in-class clinical trial that will evaluate its investigational drug candidate for the treatment of geographic atrophy (GA). Learn more on Glance: https://lnkd.in/gwfYfHbP #GlanceNews Marty Nazzaro LeBlanc Ron

Metric
Company Name	Inflammasome Therapeutics	Vision Biotechnology
Symbol
MSH ID	COM:INFLAM	COM:VISIONBIOTECHNOLOGY
Market	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Healthcare & Health Services
Industry	Biotechnology	Biotechnology
Country	US	US
Stage	Seed
Employee Count
Website	inflam.com	visionbiotechnology.com
LinkedIn	inflammasome-therapeutics	visionbiotechnolgy
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic	153	434
Web Traffic Growth	-0.45	1.39
Valuation
Raised Capital	3.80M

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

INFL

COM:INFLAM

Inflammasome Therapeutics

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue